Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | F9 | P00740 | 2/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.42 |
| ▸ | F5 | P12259 | 1/20 | 0.42 |
| ▸ | PROC | P04070 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564154 | 0.94 | F10 (0.50) | F10F2F9CTRB1F5 | |
| SCHEMBL3564844 | 0.81 | F10 (0.51) | F10F2F9CTRB1F5 | |
| SCHEMBL3564156 | 0.77 | F10 (0.51) | F10F2F9CTRB1F5 | |
| SCHEMBL3569907 | 0.73 | F10 (0.47) | F10F2CTRB1F5MEN1 | |
| SCHEMBL6459173 | 0.72 | F10 (0.55) | F10F2F9CTRB1F5 | |
| SCHEMBL6459181 | 0.72 | F10 (0.55) | F10F2F9CTRB1F5 | |
| SCHEMBL4654833 | 0.70 | F10 (0.57) | F10F2F9CTRB1F5 | |
| SCHEMBL5813906 | 0.70 | ALDH1A1 (0.44) | MEN1KMT2A | |
| SCHEMBL4626215 | 0.70 | F10 (0.56) | F10F2F9CTRB1F5 | |
| SCHEMBL3559106 | 0.69 | F10 (0.43) | F10F2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160821-A1 | Ureas as factor Xa inhibitors | TFPI, F12, F11 | F10 9/4885F2 6/4885F9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.